Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL

Clinical trial NCT06985472 · RECRUITING

Trial details

NCT number: NCT06985472
Sponsor: Li Zhiming
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Initial MZL Untreated MZL BTKi CD20

Start date: 2024-11-13
Primary completion: 2025-12-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.